1. Driving Innovation and Strategic Excellence in Life Sciences

2. Corporate Development
About Ventac Partners
We Are Experts in Life Science Business Development
Consulting Services
We provide experience-based consulting services for Biotech, Pharma and Medtech clients globally. Technical consulting, project management, strategy & management consulting, market & opportunity analyses are some of our core areas of expertise.
Corporate Development
We offer extensive buy and sell-side transaction experience with a truly international reach in virtually all Life Science sectors. Our specialties include in- and out-licensing, mergers & acquisitions, business development and marketing collaborations in all continents.
Company Creation
Ventac Partners has a global network of Life Science investors in Europe, US and Asia as well as expertise in founding and growing companies on behalf of clients. Unlike other consulting agencies, we also form, manage, grow and help exit innovative Portfolio Companies co-owned with partners & investors.

3. Why Use Ventac for Your Consulting Needs?
We Bring Real-world, Current Experience to Address Your Analytical and Operational Needs
Global Operational Experience
Strong Track Record for Product and Company Launches
Expertise from Concept to Commercialization
Market & IP Research
Competitive & Pipeline Analysis
Direct Market Feedback from Key Opinion Leaders
Due Diligence
Business Development
Product Development & Launch

4. Market Analysis A service offering that provides comprehensive analysis and insights into the current and future market and competitors
Data Collection Sources:
Secondary sources
Proprietary database and reports
(Globaldata)
Analyst reports
Comprehensive analysis from defined data sources
Data validation and quality checks
Customized reports that deliver strategic insights and market highlights most relevant to client needs
Market/
Opportunity
Assessments
Market opportunity for new/existing products or markets
Determine barriers to market entry
Assess size of opportunity

5. Market Analysis – Project Approach
Methodology Development &
Project Outline
Disease
Overview
Market Size Estimation
Data Collection and
Integrated Analysis
Consultation with Client
Epidemiology
Market
Attractiveness
Add Value Analysis/Research
Current Treatment Options
Future Outlook
Draft Report Analysis and Presentation
Current Market Landscape with Trend Analysis
Further Consultation with the Client
Pipeline Analysis/
Competitive Landscape
Unmet
Needs
Final PowerPoint Presentation

6. Competitive Intelligence
CI services address the need of a client to receive relevant, quick and important competitive information about competitive threats, business opportunities as well as market scenarios
Services offered across a wide range of therapeutic areas
The CI solution portfolio organizes and analyzes information from various sources to deliver insights that help management take important tactical and strategic decisions
Range of CI Service Offerings
Pipeline Analysis
Company/Product Profiling
Molecule Profiling
Therapy Area Analysis
Clinical Trial Maps
Disease Area Strategy Analysis

7. Pipeline Analysis Competitive grid: Bullseye chart:
Collate a list of pipeline molecules by indication
Competitive grid:
A tabular representation to highlight the number of competitive molecules by phase of development among indications of interest, allowing for top-line views and comparison
Bullseye chart:
An organized system that graphically represents the molecules in development for each indication
Detailed molecule profiles:
Profiling of late-stage molecules of interest to the client for each of the indications requested
Client files
Secondary sources
Pipeline and other relevant information from proprietary databases that client has access to
Clincaltrials.gov
Pubmed
Cancer.gov
Company websites
Organize and filter project specific information
Molecule Name
Sort and analyze pipeline information
Phase of Development
Company Name
Drug Class
Competitive
Grid
Bubble
Chart
In-depth molecule profile
Project Outputs

8. Bullseye Chart - Molecules in Development by Phase of Development and Drug class
Drug Class G
Phase I
Drug 1
Phase II
Drug Class A
Drug 2
Drug Class F 
Drug 1
Drug 4
Phase III
Drug 3
Drug 2
Drug 2
Drug 3
Drug 1
Regulatory Approval
Drug 3
Drug 1
Drug Class B
Drug 3
Drug 2
Drug 2
Drug 7
Drug 1
Drug Class C
Drug 8
Drug 6
Drug 5
Drug 1
Drug 9
Drug 4
Drug 2
Drug 3
Drug 1
Drug 6
Drug 10
Drug 3
Drug Class E
Drug 2
Drug Class D
Drug 11
Drug 4
Drug 5

9. Pipeline Tracking and Analysis
Clearly presented results coupled with strategic insights and recommendations
Pipeline Tool
PowerPoint Reports

10. Product Profiling Research Scope
Total Sales
Product Strength
Product Risk Assessment
Competitive Landscape
Latest News
Sales forecast
Secondary Searches
Annual Reports
Analyst Reports
Investor Relation reports
KOL Interviews
Proprietary Databases
A Word/PowerPoint report providing detailed and customized profiling of in-market products across parameters defined by client

11. Molecule Profiling
Current phase of development for each indication
Originator/Licensee(s)
Mechanism of Action
Route of Administration
Safety & Efficacy report
Developmental History
Detailed profiles with latest clinical study results and ongoing trials

12. Third Party IP/FTO Assessment
Review of initial Freedom to Operate search - outsourced to searching experts) to identify potentially problematic granted and in-force patents and pending patent applications
Technical assessment of main patent documents of concern in conjunction with client technical experts
If necessary and approved, assistance with assessment of potential infringement and validity of identified patents/applications with appropriate patent attorneys in the relevant territories
Third Party IP Assessment
Outsourced Search
Review of Results
Problem Patents
Assessment of Relevance/Risk
Law Firm Opinion
Strategic Recommendations

13. Our Presence We have access to the expertise of our 19 partners across the globe. Specific partners are chosen for a project based on individual expertise.
Trondheim
Lund
London
Copenhagen
Düsseldorf
Munich
Boston
Boulder
Basel
Madrid
San Francisco
Shanghai
San Diego

14. Our International Team
Mikael
Ørum
Scott
Woodward
Martin
Austin
Dede
Willis
Robert
Buchanan
Peter
Damsbo
Melya Hughes
Crameri
Lars
Hedbys
Jonathan
Myers
Pharma – Biotech – Medtech
Rolf
Ehrnstrom
Neil
Thomas
Kostas
Alevizopoulos
Aarti
Kapoor
Dennis
Henriksen
Randi
Berholtz
Bengt
Westrin
Mirko
Stange
Henrik
Stage
Joe Tucker

15. Track Record Summary
Our team offers more than 300 years of international experience in growing technology into successful businesses, both as entrepreneurs in start-up companies and as senior managers in pharma, biotech and CROs. Since the foundation of Ventac Partners in 2002, the team has:
assessed more than 1000 invention disclosures and business plans from life science researchers and entrepreneurs
raised more than EUR 250 million in funding for start-up and growth stage companies
incorporated and grown more than 15 spin-out companies with inventors/universities/large companies as co-owners
negotiated large technology and drug licenses in USA, Europe, Japan and China
provided board level strategic input to companies and governments
delivered turn-around teams to companies in distress or in need of a sharper commercial profile and/or successful business development impact in the market place

16. Driving Innovation and Strategic Excellence in Life Sciences